Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis

Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk

(2012) Toshitaka Nakamura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

(2012) M. Shiraki et al.   OSTEOPOROSIS INTERNATIONAL

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

(2010) Akimitsu Miyauchi et al.   BONE

Suppression of Wnt Signaling by Dkk1 Attenuates PTH-Mediated Stromal Cell Response and New Bone Formation

(2010) Jun Guo et al.   Cell Metabolism

Vertebral fracture assessment using a semiquantitative technique

(2010) Harry K. Genant et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects

(2009) Wei Yao et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis

(2008) Athanasios D. ANASTASILAKIS et al.   ENDOCRINE JOURNAL

Parathyroid hormone signaling through low-density lipoprotein-related protein 6

(2008) M. Wan et al.   GENES & DEVELOPMENT